A Trotter1, L Maier, M Kron, F Pohlandt. 1. Section of Neonatology and Pediatric Critical Care Medicine, Children's Hospital, University of Ulm, Ulm, Germany. andreas.trotter@web.de
Abstract
OBJECTIVE: To study whether postnatal replacement of oestradiol and progesterone may help to prevent bronchopulmonary dysplasia (BPD). METHODS: This randomised placebo-controlled double-blind study enrolled 83 infants of <29 weeks gestational age and 1000 g birth weight requiring mechanical ventilation within 12 h after birth. Oestradiol (2.5 mg/kg/day) and progesterone (22.5 mg/kg/day) were given by continuous intravenous infusion of a standard lipid emulsion (15 ml/kg/day) in the replacement group (ESTRA-PRO). The placebo group received the same lipid emulsion without oestradiol or progesterone. A replacement period of at least 2 weeks but not >4 weeks was strived for and defined as "according to protocol". The primary outcome variable was the incidence of BPD or death. RESULTS: The median birth weight was 670 g (min-max 400-990 g) and the gestational age 25 weeks (23.1-28.1 weeks). The incidence of BPD or death was 48% in the placebo group and 44% in the ESTRA-PRO group (p = 0.38, one-sided testing, intention to treat analysis). In infants treated according to protocol, 32% (9 of 28) in the placebo group and 14% (3 of 21) in the ESTRA-PRO group developed BPD (p = 0.08). CONCLUSION: Replacement of oestradiol and progesterone was not effective for prevention of BPD or death in extremely preterm born infants. Better-powered trials are needed to evaluate this new approach.
RCT Entities:
OBJECTIVE: To study whether postnatal replacement of oestradiol and progesterone may help to prevent bronchopulmonary dysplasia (BPD). METHODS: This randomised placebo-controlled double-blind study enrolled 83 infants of <29 weeks gestational age and 1000 g birth weight requiring mechanical ventilation within 12 h after birth. Oestradiol (2.5 mg/kg/day) and progesterone (22.5 mg/kg/day) were given by continuous intravenous infusion of a standard lipid emulsion (15 ml/kg/day) in the replacement group (ESTRA-PRO). The placebo group received the same lipid emulsion without oestradiol or progesterone. A replacement period of at least 2 weeks but not >4 weeks was strived for and defined as "according to protocol". The primary outcome variable was the incidence of BPD or death. RESULTS: The median birth weight was 670 g (min-max 400-990 g) and the gestational age 25 weeks (23.1-28.1 weeks). The incidence of BPD or death was 48% in the placebo group and 44% in the ESTRA-PRO group (p = 0.38, one-sided testing, intention to treat analysis). In infants treated according to protocol, 32% (9 of 28) in the placebo group and 14% (3 of 21) in the ESTRA-PRO group developed BPD (p = 0.08). CONCLUSION: Replacement of oestradiol and progesterone was not effective for prevention of BPD or death in extremely preterm born infants. Better-powered trials are needed to evaluate this new approach.
Authors: Stiliani Asimiadou; Petra Bittigau; Ursula Felderhoff-Mueser; Daniela Manthey; Marco Sifringer; Stefanie Pesditschek; Mark Dzietko; Angela M Kaindl; Maria Pytel; Dorota Studniarczyk; Jerzy W Mozrzymas; Chrysanthy Ikonomidou Journal: Ann Neurol Date: 2005-08 Impact factor: 10.422
Authors: I Suzuma; M Mandai; H Takagi; K Suzuma; A Otani; H Oh; K Kobayashi; Y Honda Journal: Invest Ophthalmol Vis Sci Date: 1999-08 Impact factor: 4.799
Authors: Andreas Trotter; Michael Ebsen; Evangelos Kiossis; Sabine Meggle; Eva Kueppers; Cordian Beyer; Frank Pohlandt; Ludwig Maier; Ulrich H Thome Journal: Pediatr Res Date: 2006-05-11 Impact factor: 3.756
Authors: Donald C McCurnin; Richard A Pierce; Brigham C Willis; Ling Yi Chang; Bradley A Yoder; Ivan S Yuhanna; Philip L Ballard; Ronald I Clyman; Nahid Waleh; William Maniscalco; James D Crapo; Peter H Grubb; Philip W Shaul Journal: Am J Respir Crit Care Med Date: 2009-01-16 Impact factor: 21.405